Le Infezioni in Medicina, n. 1, 58-67, 2019
58 ORIGINAL ARTICLE
Efficacy of 5-nitroimidazole
compounds for giardiasis in Cuban
children: systematic review
and meta-analysis
Angel A. Escobedo1,2, Pedro Almirall3, Eduardo González-Fraile4, Javier Ballesteros5
Academic Paediatric Hospital “Pedro Borrás”, La Habana, Cuba;
Working Group on Zoonoses, International Society for Chemotherapy, Aberdeen, United Kingdom;
3
Municipal Centre of Hygiene, Epidemiology and Microbiology “Plaza”, La Habana, Cuba;
4
International University of La Rioja (UNIR), Logroño;
5
University of the Basque Country UPV/EHU and CIBERSAM. Medical School, Department of Neuroscience,
Leioa, Spain
1
2
SUMMARY
Five-nitroimidazole (5-NI) compounds are among the
most commonly used medications in the treatment
of giardiasis. However, after more than five decades
of their initial indication for such treatment, there are
some concerns about the efficacy of 5-NIs in giardiasis.
This study sought to compare the efficacy of any 5-NI
with any other antigiardial drug for the treatment of
Cuban children with giardiasis. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). We searched CUMED, EBSCOhost
and PubMed databases. Two reviewers independently assessed trial eligibility, trial quality and extracted
appropriate data. The primary outcome was the parasitological cure. The effect estimate was the pooled
relative risk (RR) with 95% confidence intervals (CI).
We included seven RCTs in the systematic review,
n INTRODUCTION
iardia lamblia, the first protozoan agent associated with human disease, has a world-wide
distribution. It is transmitted through the faecal-oral route following direct or indirect contact
with environmentally resistant cysts, principally,
via contaminated water and food. Giardiasis, the
G
Corresponding author
Angel A. Escobedo
E-mail: escobedo@infomed.sld.cu
involving a total of 1046 children. When the effect of
5-NIs was compared with that of benzimidazole compounds, the pooled effect was significant and favored
5-NIs [the relative risk (RR) is 1.35, 95% CI =1.05
to
2
1.75], with high heterogeneity (4 studies, I =79%).
Compared with chloroquine, the pooled effects of the
5-NIs were not significant [RR is 0.96, 95% CI=0.79 to
1.18, (2 studies, I2=68%)]. Our results support the use of
5-NIs (mainly tinidazole) as first-line therapy for Cuban pediatric patients infected with Giardia and may
continue being used as reference drugs in future RCTs
of giardiasis. These data could help inform policy decisions in Cuba. Caution is needed in extrapolating such
data in other settings.
Keywords: nitroimidazole, giardiasis
disease it causes, is an important public health
problem, mainly for low- and middle-income
countries, where it is considered to be an important cause of morbidity [1]. It is estimated that giardiasis causes annually 184 million clinical cases
and an associated 171,100 (115,777-257,315) disability-adjusted life years [2, 3].
In Cuba, a national prevalence survey, conducted in 2009, found an overall prevalence of Giardia
infection of 6.02%, similar to the former prevalence of 7.2% found in the 1984 national survey
[unpublished report]. However, a higher prevalence is reported in other settings including day-
Five-nitroimidazole drugs in Cuban children 59
care centres and primary schools [4-8]. Although
Giardia affects people of all conditions and ages,
children are at greatest risk to present giardiasis,
presumably because of poor hygiene as a facilitator of the faecal-oral transmission of Giardia cysts
[9]. Clinical giardiasis seems to be also a common
reason for hospitalisation in paediatric hospitals
in Havana, the capital of Cuba [10-12].
Effective antigiardial chemotherapy began in 1940s
with quinacrine (QC), an acridine derivative first
introduced for malaria therapy in the 1930s, [13].
QC was replaced by other drugs, as metronidazole
(MTZ) and other 5-nitroimidazole (5-NI) compounds [tinidazole (TNZ), ornidazole, secnidazole
(SNZ)], and also with nitrofuranes (furazolidone)
and aminoglycosides (paromomycin) [14, 15].
Currently, 5-NI compounds are the recommended
first line therapy for children and adults infected
with Giardia [1]. However, some individuals experience treatment failures, despite having received
successive courses of treatment that have been documented to result in a cure for most patients [16].
Additionally, non-clinical factors such as patient
expectations and demand, and misperceptions
about efficacy of antigiardial drugs, principally
MTZ, are important issues in the Cuban population which could impact on the prescription of
5-NIs as first-line drugs to treat giardiasis [17, 18].
Several systematic reviews and/or meta-analyses
on the efficacy of treatments for giardiasis have
been published, and although the efficacy of antigiardial drugs is known, there is a lack of knowledge in Cuba, about treatment efficacy within
homogeneous groups of children, and its determinants [19-24]. Therefore, the objective of this
systematic review and meta-analysis is to properly document and evaluate the current evidence
on the efficacy of 5-NIs in the treatment of Cuban children with Giardia infection. With this review we hope to produce and provide a reliable,
convenient and evidence-based summary of the
primary literature in support of policy decisions
both in Cuba and other similar countries.
n MATERIALS AND METHODS
This review and meta-analysis was conducted
according to the Preferred Reporting Items for
Systematic Reviews and Meta-analysis (PRISMA)
statement [25].
Search strategy
Electronic literature searches are current to March
15, 2018. We searched the following computerized
biomedical databases: CUMED, PubMed, and EBSCOhost; all of them from 2000 to 2017. CUMED
is a specific Cuban bibliographic database that records the Cuban scientific production in medical
and related sciences. It includes bibliographic references and summaries of journal articles, books
or book chapters, academic thesis, and congresses
communications published in Cuba or outside
Cuba by Cuban authors. We used combinations
of free and controlled language for the following
terms: Giardia OR giardiasis for CUMED; Giardia
OR giardiasis AND Cuba OR Cuban AND “randomized clinical trial” for PubMed; and Giardia OR
giardiasis AND Cuba OR Cuban, for EBSCOhost.
We did not apply language restrictions. If needed
the corresponding authors were contacted for further information to assess methodological details
and supplementary data. Abstracts and full text
papers from eligible studies were reviewed, and
those meeting our predefined selection criteria
were considered for inclusion.
Inclusion and exclusion criteria
The inclusion criteria were: (i) RCTs evaluating
the efficacy of 5-NI with a control condition (placebo, another active treatment); (ii) study population of patients with parasitologically-demonstrated giardiasis and measured parasitological
cure (defined as a negative Giardia in faecal specimens at the follow-up); (iii) previously untreated
patient population, (iv) full text study available or
supplementary data provided by corresponding
authors on request, and (v) included participants
aged <18 years.
We excluded studies if: (i) they included a mixed
population of adults and children and responses
of the two groups were not differentiated; and (ii)
efficacy data (parasitological cure rates) were not
available or could not be obtained for the study
groups.
Study selection and data extraction
The list of retrieved articles was independently
reviewed by two investigators (AAE and PA), and
disagreements were discussed and resolved by
consensus. The same investigators independently
extracted data characteristics and effect sizes for
the included studies.
60 A.A. Escobedo, et al.
We extracted the following information: (1) study
author, and year of publication; (2) study characteristics (study setting, duration of follow-up, and
sample size); (3) participant characteristics (participants by treatment arm sex, and age); (4) diagnostic
test used for giardiasis and for assessing parasitological cure; (5) presence of signs and/or symptoms
at diagnosis; characteristics of interventions (including the type of 5-NI and dose/duration, comparator drug and dose/duration). Another author
(JB) reviewed the data extraction forms for inconsistencies and discrepancies were resolved by discussion prior to include data in the meta-analysis.
Outcome
The primary outcome measure was the parasitological efficacy defined as the absence of detectable Giardia cysts or trophozoites at the end of the
treatment in at least two consecutive faecal microscopic examinations.
Assessment of methodological quality
Studies that met inclusion criteria were graded for
methodological quality using a scale reported by
Jadad et al. [26]. Jadad quality scores are based on
the description and appropriateness of randomization, adequacy and appropriateness of blinding,
and descriptions of withdrawals and dropouts,
and can range from 0 to 5, with higher scores indicating better methodological quality (i.e., a score of
0-2 was considered as low quality trial and a score
of 3-5 was considered high quality trial). The quality of parasitological diagnostic methods was separately assessed by the scoring system utilised by
Zaat et al. and Solaymani-Mohammadi et al. This
method evaluates whether techniques are sufficiently described and adequate [19, 20].
Statistical analysis
We used as effect size the pooled relative risk (RR)
with 95% confidence intervals (CI). A 95% CI for
the RR that does not include the value for the null
hypothesis of no difference (RR=1) favors 5-NI
treatment for all comparisons. Heterogeneity (degree of difference between the results of different
trials) was assessed with the I2 index that estimate
the proportion of total variability in pooled estimates that could be attributed to between-trials
heterogeneity, rather than by a chance [27].
We pooled effect sizes with the Mantel-Haenszel
method using a random effects model and if data
permitted we also estimated a predictive value for
the RR that could be expected for new studies [28].
We performed a supplementary analysis pooling
efficacy rates within treatments to enhance the interpretation of the comparative analyses.
Statistical analyses were performed with the R
package using the library meta [29, 30].
n RESULTS
Search results
The initial search yielded 125 records (65 from
CUMED, 52 from EBSCOhost and 8 from PubMed), of which 111 remained after removal of
duplicates (see PRISMA flow diagram, Figure
1). Through a review of titles and abstracts, 103
studies were rejected as irrelevant. The remaining
potentially relevant seven articles were reviewed
and assessed for satisfaction of the inclusion or
exclusion criteria. The seven articles met all criteria and were included in the analysis. References
cited in the retrieved articles were manually reviewed to identify additional published work not
indexed in the databases but we did not find any
fitting our inclusion criteria.
Description of included studies
In the present analysis 5-NIs were compared with
benzimidazoles (3 comparisons), chloroquine (2
comparisons), aminosidine (1 comparison) and
nitazoxanide (1 comparison) [31-37]. The key
characteristics of the included studies are presented in Table 1.
Study characteristics and methodological quality
The seven studies (Table 1) included a total of
1046 children. All studies were conducted in
outpatient population. Samples sizes were small
(ranging from 92 to 256, duration of 5-NI regimen
varied from 1 day, 5 days, to 7 days. All trials were
open. The post-treatment follow-up time varied
across the studies from 7 days to 21 days [31-37].
By the quality of studies evaluated by Jadad scale;
all studies were considered of high quality (Table
2). All studies were described as randomized, and
all of them described appropriately the randomization procedure. Although none of the studies
were appropriately blinded for participants, in
all of them the laboratory personnel checking the
post treatment fecal samples were unaware of the
treatment allocation. Loss of follow-up did not
Five-nitroimidazole drugs in Cuban children 61
occur in six studies whereas one study reported
patient withdrawals [37].
Parasitological examination
In all studies, the absence of detectable Giardia
trophozoites and/or cysts in the fecal microscopy
during the follow-up period was required to declare the children cured. All studies implemented
two different parasitological methods for diagnosis at the same time (direct fecal microscopy in
combination with ether concentration technique).
All trials scored 8 points out of a maximum of 15,
indicating a modest quality. It was mainly due to
the relatively great weight of the item “repeated
examinations at follow-up”. Inter-observer variation was not described in any trial (Table 3).
The quality of parasitological examinations was
assessed according to the following:
– Description of technique: Two points for a description of the laboratory technique. Rate 0 if
there is only a statement about “parasitological examination” without further description.
– Adequate techniques: in each study, we first distinguished whether a fresh stool specimen, fixed
or a duodenal aspirate (where a duodenoscopy
and brush) was used. Then the examination
technique was scrutinized, scoring as tabulated.
– Credit points:
- one credit point if more than one technique
is used at the same time;
- one credit point if fresh and fixed stools are
examined at the same time;
- one credit point if stool specimen and duodenal aspirate are used at the same time.
– Repeated examinations: Rate 3 when more
than one stool specimen was examined at dif-
Fresh
Fixed
Duodenal aspirate
Direct (saline, eosine, Lugol)
0
0
1
Concentration (Faust, Ritchie, etc.)
2
3
0
Immunological (ELISA)
3
3
0
Permanent stained smear
0
4
4
Identificatio
Identi
tio
n
n
ScreeningScre
Records identified
through database
searching
(CUMED n=65)
(PubMed n=8)
(EBSCOhost n=52)
Additional records
identified through other
sources
(n=0)
Records after duplicates removed
(n=111)
Records excluded
(n=103)
Eligibility Elig
Included
clud
Full-text articles
assessed for eligibility
(n=7)
Studies included in
quantitative synthesis
(meta-analysis)
(n=7)
Figure 1- Search strategy for
identification of articles (Flow
chart).
62 A.A. Escobedo, et al.
Table 1 - Characteristics of the randomized controlled trials included in the meta-analysis
Author, Year
[Reference]
Study
design
No. of
randomized
participants
Age
(y)
Sex
M/F
Disease
characteristics
Diagnostic test
Antigiardial drug
regimens
(No. of
participants)
Efficacy
Follow-up
Mendoza
et al.,
2003
[31]
Openlabel,
RCT
2 parallel
arms
92
2-5
47/45
Symptomatic
and
asymptomatic
Direct wet
mount and
formol ether
sedimentation
ABZ, 400 mg/d
for 5 days (49)
17/49
(34.6%)
TNZ, 50 mg/
kg (max. 2g) s.d.
(43)
31/43
(72.0%)
Day 7,
14 & 21
after
treatment
Escobedo
et al.,
2003 [32]
Openlabel,
RCT
2 parallel
arms
146
Symptomatic
Direct wet
mount and
formol ether
sedimentation
technique
methods
MBZ, 200 mg tid
for 3 days (73)
57/73
(78.1%)
SNZ, 30 mg/kg
s.d. (73)
58/73
(79.4%)
Escobedo
et al.,
2003 [33]
Openlabel,
RCT
3 parallel
arms
165
ABZ, 400 mg/
day for 5 days
(60)
37/60
(62.0%)
CQ, 10 mg/kg
twice daily for 5
days (50)
43/50
(86%)
TNZ, 50 mg/
kg (max. 2g) s.d.
(55)
50/55
(91.0%)
Aminosidine,
35 mg divided
into 3 doses for
7 days (59)
54/59
(91.5%)
MTZ, 25 mg/
kg divided into
three doses for 7
days (89)
71/89
(79.8%)
MBZ, 200 mg
tid, 1 day (61)
39/61
(63.9%)
TNZ, 50 mg/
kg, (max. 2g)
s.d. (61)
50/61
(81.9%)
Núñez et
al., 2004
[35]
Openlabel,
RCT
2 parallel
arms
256
Cañete et
al., 2006
[34]
Openlabel,
RCT
2 parallel
arms
122
Escobedo
et al.,
2008 [37]
Openlabel,
RCT
2 parallel
arms
166
Openlabel,
RCT
2 parallel
arms
122
Cañete et
al, 2010
[36]
5-15
2-15
1-5
5-15
5-14
5-15
80/66
58/57
122/134
63/59
87/79
70/52
Symptomatic
Asymptomatic
Symptomatic
Symptomatic
and
asymptomatic
Symptomatic
Direct wet
mount and
formol ether
sedimentation
technique
methods
Direct wet
mount and
formol ether
sedimentation
technique
methods
Direct wet
mount and
formol ether
sedimentation
Direct wet
mount and
formol ether
sedimentation
Direct wet
mount and
formol ether
sedimentation
NTZ, 7.5 mg/
kg bid for 3 days
(85)
58/74 pp
(78.4%)
58/85 iit
(68.2%)
TNZ, 50 mg/
kg, (max. 2g)
s.d. (81)
57/63 pp
(90.5%)
57/81 itt
(70.3%)
CQ, 10 mg/kg
bid for 5 days
(61)
52/61
(85.2%)
MTZ, 15 mg/
kg divided into
three doses for 7
days (61)
45/61
(73.7%)
Days 3, 5
& 7 after
treatment
Day 7 &
10 after
treatment
Day 7,
14 & 21
after
treatment
Day 3, 5
& 7 after
treatment
Day 5
& 10
Day 3,
5 & 10
after
treatment
Five-nitroimidazole drugs in Cuban children 63
Table 2 - Jadad scoring of included studies
Author [Reference]
Study
described as
randomized
Method used to
generate the sequence
of randomization
described and
appropriate
Study
described
as double
blind
Method of double
blinding described
and appropriate
Study described
withdrawals
and dropouts
Total
Jadad
score
Mendoza et al., [31]
1
1
1
1
1
5
Escobedo et al., [32]
1
1
1
1
1
5
Escobedo et al., [33]
1
1
1
1
1
5
Núñez et al. [35]
1
1
1
1
1
5
Cañete et al., [34]
1
1
1
1
1
5
Escobedo et., [37]
1
1
1
1
1
5
Cañete et al., [36]
1
1
1
1
1
5
Table 3 - Parasitological quality of included studies
Parasitological examination
Author [Reference]
Description
Adequate
Repeated
Interobserver variation
Total*
Mendoza et al., [31]
2
3
3
0
8
Escobedo et al., [32]
2
3
3
0
8
Escobedo et al., [33]
2
3
3
0
8
Núñez et al. [35]
2
3
3
0
8
Cañete et al., [34]
2
3
3
0
8
Escobedo et., [37]
2
3
3
0
8
Cañete et al., [36]
2
3
3
0
8
*Range 0-15; 15 indicates optimal laboratory technique
ferent follow up time, otherwise rate 0.
– Interobserver variation: Rate 3 when inter/
intra observer variation is described or mentioned; otherwise rate 0.
5-NIs versus benzimidazoles
There are 4 studies giving evidence for this
comparison including 232 participants randomized to 5-NIs (73 to SNZ, 159 to TNZ), and
243 participants randomized to benzimidazoles
(134 to mebendazole (MBZ), 109 to albendazole
(ABZ)) [31-34]. The pooled effect was significant and favored 5-NIs (RR=1.35, 95% CI=1.05
to 1.75, I2=79%) with a wide prediction interval (0.43 favouring benzimidazoles to 4.22 favouring 5-NIs). By interventions, SNZ efficacy
was similar to MBZ (1 study, 146 participants,
RR=1.02, 95% CI=0.86 to 1.20). TNZ was significantly better than ABZ (2 studies, 207 participants, RR=1.67, 95% CI=1.19 to 2.36, I2=55%).
TNZ was significantly better than MBZ (1 study,
122 participants, RR=1.28, 95% CI=1.03 to 1.60).
See figure 2.
5-NIs versus chloroquine
There are 2 studies giving evidence for this comparison including 116 participants randomized to
5-NI (61 to MTZ, 55 to TNZ), and 111 participants
randomized to chloroquine [33,36]. The pooled effect was not significant (RR=0.96, 95% CI=0.79 to
1.18, I2=68%). There was not enough information
to estimate a prediction interval. By interventions,
MTZ was worse than chloroquine but not statistically significant (1 study, 122 participants, RR=0.87,
95% CI=0.72 to 1.04). TNZ was not significantly
different to chloroquine (1 study, 105 participants,
RR=1.06, 95% CI=0.92 to 1.22). See figure 3.
5-NIs versus aminosidine
We found one study including 89 participants
randomized to MTZ and 59 participants rand-
64 A.A. Escobedo, et al.
omized to aminosidine. The study presented adequate methods of randomization and allocation
concealment, but inadequate follow-up [35]. The
effect was significant and favored aminosidine
(RR=0.87, 95% CI=0.77 to 0.99).
5-NIs versus nitazoxanide
We found one study including 81 participants
randomized to tinidazole and 85 participants randomized to nitazoxanide. The study presented
adequate methods of randomization, allocation
Figure 2 - Forest plot showing the effects of 5-NIs and benzimidazole compounds in giardiasis in Cuban children.
Figure 3 - Forest plot showing the effects of 5-NIs and chloroquine in giardiasis in Cuban children.
Five-nitroimidazole drugs in Cuban children 65
concealment and follow-up [37]. The effect was
not significant (RR=1.03, 95% CI=0.84 to 1.26).
n DISCUSSION
This systematic review with meta-analysis provides a PRISMA-compliant, internationally accessible, and timely review on the efficacy of
5-NI compounds for Giardia infection in Cuban
children. We identified, extracted, and evaluated
data from a collection of clinical studies of various treatments for Giardia infection carried out in
Cuba between 2000 and 2017.
Whether 5-NIs therapy in giardiasis should continue as first-line therapy is currently under debate. Our results showed that in a population
of <18 years of age Cuban children with Giardia
infection, assisted in the outpatient setting, there
was a statistically significant therapeutic benefit
favoring the use of 5-NIs, supporting the recommendation of the Cuban pediatric guidelines,
which recommend 5-NIs as first-line treatment
for giardiasis in patients [38].
In the present systematic review and meta-analysis, TNZ is regarded as the best available option
for the treatment of Giardia infection in Cuban
children. This drug, with a similar structure to
MTZ but with a longer half-life and more favorable side effect profile, has been used for decades
in Cuba. Due to its pharmacokinetics, it is possible to be used as a single dose therapy. The good
tolerance of TNZ is also considered an advantage
in terms of patients’ compliance. All of these features result in superior cure rates compared with
other antigiardial drugs for the treatment of giardiasis. However, as 5-NI drugs share common
mechanism of activation by Giardia trophozoites,
it is wise to suspect that a cross-resistance between them could occur. However, variations in
pharmacokinetics and bioavailability of drugs
have been noted that may influence their efficacy in clinical setting and, in the case of TNZ, it
may be used in cases where a previous MTZ treatment has failed [39]. Other extra benefits of TNZ
include that symptoms like diarrhoea have been
reported to ameliorate earlier when treating with
TNZ in comparison with MTZ and parasitological cure rates have also been proven earlier, higher or comparable when both drugs are evaluated
[40-44].
Strengths and limitations
As with any meta-analysis, the strength of the
findings reflects the quality of the underlying
data, potential for publication bias, and heterogeneity. The comprehensive search, attempts to
identify data in a Cuban database. All included
studies had a Jadad quality score of 5 and the
authors of the included studies were contacted
to retrieve unpublished data. However, we must
also consider its limitations. First, the sample size
of this meta-analysis was relatively small, which
may reduce the power of statistical analysis. Second, only published studies were included in the
present meta-analysis; thus, publication bias may
have occurred. Third, we have not been able to
relate the outcome of the studies to the dose and
dosing of the drugs given. Fourth, there was no
data to make conclusions regarding ornidazole
due to lack of availability of this drug in the Cuban market. Fifth, all studies referred to a generic diagnosis of “giardiasis”, without distinction
among acute, recurrent or the chronic forms of
this parasitic disease. Finally, although the analysis is based on patients enrolled in RCTs, they
may not be representative of the broader patient
population seen in clinical practice. Enrolled patients have strict eligibility criteria and those who
agree to participate may have higher adherence
profile compared to unselected patients and be
very different from the general population.
Despite these limitations, the value of this meta-analysis lies in its combination of data from
several Cuban RCTs, which resulted in demonstration of differences in some aspects of the effectiveness of the treatments. Most of the differences
observed were of marginal statistical significance,
and RCTs with large sample sizes would be required to manifest these differences.
How can pediatricians and family doctors use
the results of this meta-analysis? From the studies identified, it is reassuring to see that treatment
effects of 5-NIs have been monitored in Cuba
during the last years, and alternative treatment
options actively sought. However, limited or no
data exist for some drugs; some of them deserve
more studies. Our analysis, which included recently trials published since the year 2000 to 2017,
supports the use of 5-NIs (specifically, MTZ, TNZ
and SNZ) as drugs of choice for first-line therapy
of Giardia infections in Cuban children. There is
no reason to be reluctant to prescribe such thera-
66 A.A. Escobedo, et al.
py due to its well-documented efficacy. Benzimidazole compounds and chloroquine may offer an
alternative to 5-NIs but do not make them obsolete. MTZ and TNZ have been in clinical use for
years with extensive amount of post-marketing
data available. More post-marketing information
regarding its efficacy for Giardia infections in children is needed on ornidazole for comprehensive
pharmacovigilance.
n CONCLUSIONS
This study extends the results of previous meta-analyses and offers an objective picture of
the current status of the 5-NIs efficacy in Giardia
infections in Cuban children. Our results also
support that 5-NIs may continue being used as
reference drugs in future RCTs in children with
giardiasis. Of the drugs tested, TNZ appears to be
the most efficacious option currently available for
treatment of Giardia infections in Cuban children.
Well-designed, multi-centre Giardia eradication
trials in children are currently lacking and are critically needed, as some treatment options have not
yet been tested in Cuba (i.e., ornidazole), where
the prevalence of this infection and associated
disease burden in paediatric population seems to
be high. Despite availability and use of 5-NIs for
more than 5 decades, our data support the Cuban
recommendations that these drugs be considered
as first-line therapy for giardiasis.
Authorship contribution
All authors contributed to the design of the
study, planning, analysis, and interpretation of
the results as well as to the writing of the paper.
All authors have approved the final version for
publication. All authors had full access to all the
data in the study and take responsibility for the
integrity of the data and the accuracy of the data
analysis.
ACKNOWLEDGEMENTS
JB is supported through a University of the Basque
Country research grant (GIU14/27).
Disclosure
Authors have no conflict of interests, and the
work was not supported or funded by any drug
company.
n REFERENCES
[1] Einarsson E., Ma’ayeh S., Svärd S.G. An up-date on
Giardia and giardiasis. Curr. Opin. Microbiol. 34, 47e52,
2016.
[2] Pires S.M., Fischer-Walker C.L., Lanata C.F., et
al. Aetiology-specific estimates of the global and regional incidence and mortality of diarrhoeal diseases
commonly transmitted through food. PLoS One 10,
e0142927, 2015.
[3] Kirk M.D., Pires S.M., Black R.E., et al. World health
organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoan, and
viral diseases, 2010: a data synthesis. PLoS Med. 12,
e1001921, 2015.
[4] Rojas L., Núñez F.A., Aguiar P.H., et al. Segunda encuesta nacional de infecciones parasitarias intestinales
en Cuba, 2009. Rev. Cubana Med. Trop. 64, 15-21, 2012.
[5] Núñez F.A., Hernández M., Finlay C.M. Longitudinal study of giardiasis in three day care centres of Havana City. Acta Trop. 73, 237-242, 1999.
[6] Mendoza D., Núñez F.A., Escobedo A., et al. Parasitosis intestinales en 4 círculos infantiles de San Miguel
del Padrón, Ciudad de la Habana, 1998. Rev. Cubana
Med. Trop. 53, 189-193, 2001.
[7] Arencibia A.A., Escobedo A.A., Núñez F.A., Almirall P. Parásitos intestinales en niños que asisten a una
escuela primaria urbana de Ciudad de la Habana. Bol
IPK 11, 58-59, 2001.
[8] Escobedo A.A., Cañete R., Núñez F.A. Prevalence
and risk factors and clinical features associated with
intestinal parasitic infections in children from San Juan
y Martínez, Pinar del Río, Cuba. West Indian Med. J. 57,
377-382, 2008.
[9] Rojas Rivero L., Núñez Fernández F.A., Robertson
L.J. Cuban parasitology in review: a revolutionary triumph. Trends Parasitol. 24, 440-448, 2008.
[10] Escobedo A.A., Almirall P., Alfonso M., et al. Hospitalization of Cuban children for giardiasis: a retrospective study from a paediatric hospital on Havana.
Ann. Trop. Med. Parasitol. 105, 47-56, 2011.
[11] Bello J., Núñez F.A., González O.M., Fernández R.,
Escobedo A.A. Risk factors for Giardia infection among
hospitalized children in Cuba. Ann. Trop. Med. Parasitol.
105, 57-64, 2011.
[12] Escobedo A.A., Almirall P., Salazar Y., Ávila I., Alfonso M. Care seeking behaviour and diagnostic processes for symptomatic giardiasis in children attending
an academic paediatric hospital. Pathog. Glob. Health
108, 271-278, 2014.
[13] Thomas M.E. Observations upon the effects of mepacrine and other substances on Giardia intestinalis. Parasitology 42, 262-268, 1953.
[14] Darbon A., Portal A., Girier L., Pantin J., Leclaire
C. Treatment of giardiasis (lambliasis) with metronidazole. apropos of 100 cases. Presse Med. 70, 15-16, 1962.
Five-nitroimidazole drugs in Cuban children 67
[15] Minetti C., Chalmers R.M., Beeching N.J., Probert
C., Lamden K. Giardiasis. BMJ 355, i5369, 2016.
[16] Robertson L.J., Hanevik K., Escobedo A.A., Mørch
K., Langeland N. Giardiasis - why do the symptoms
sometimes never stop? Trends Parasitol. 26, 75-82, 2010.
[17] Escobedo A.A., Almirall P., Alfonso M., et al. Caregiver perspectives for the prevention, diagnosis and
treatment of childhood giardiasis in Havana City,
Cuba. A qualitative study. Acta Trop. 11, 99-106, 2011.
[18] Almirall P., Escobedo A.A., Salazar Y., et al. Parental perceptions of giardiasis. A study in an outpatient
paediatric hospital setting in Havana, Cuba. ISRN Prev.
Med. Article ID 344647, 9 pages, 2013.
[19] Zaat J.O., Mank T.G., Assendelft W.J. Drugs for
treating giardiasis. Trop. Med. Int. Health. 2, 63-82, 1997.
[20] Solaymani-Mohammadi S., Genkinger J.M., Loffredo C.A., Singer S.M. A meta-analysis of the effectiveness of albendazole compared with metronidazole as
treatments for infections with Giardia duodenalis. PLoS
Negl. Trop. Dis. 4, e682, 2010.
[21] Granados C.E., Reveiz L., Uribe L.G., Criollo C.P.
Drugs for treating giardiasis. Cochrane Database Syst.
Rev. 12, CD007787, 2012.
[22] Pasupuleti V., Escobedo A.A., Deshpande A., Thota
P., Roman Y., Hernandez A.V. Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials. PLoS Negl. Trop.
Dis. 8, e2733, 2014.
[23] Escobedo A.A., Ballesteros J., González-Fraile E.,
Almirall P. A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia
infections in children. Acta Trop. 153, 120-127, 2016.
[24] Ordóñez-Mena J.M., McCarthy N.D., Fanshawe
T.R. Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network
meta-analysis of randomized clinical trials. J. Antimicrob. Chemother. 2017 Nov 27. doi: 10.1093/jac/dkx430.
[25] Moher D., Shamseer L., Clarke M., et al. PRISMA-P
Group. Preferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, 1, 2015.
[26] Jadad A.R., Moore R.A., Carroll D., et al. Assessing
the quality of reports of randomized clinical trials: is
blinding necessary? Control Clin. Trials 17, 1-12, 1996.
[27] Higgins J.P., Thompson S.G., Deeks J.J., Altman
D.G. Measuring inconsistency in meta-analyses. BMJ
327, 557-560, 2003.
[28] Higgins J.P., Thompson S.G., Spiegelhalter D.J. A
re-evaluation of random-effects meta-analysis. J. R.
Stat. Soc. Ser. A. Stat. Soc. 172, 137-159, 2009.
[29] R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/
[30] Schwarzer G. meta: An R package for meta-analysis. R News. 7, 40-45, 2007.
[31] Mendoza D., Nuñez F.A., Escobedo A.A., et al. Utilidad de dos métodos coproparasitológicos y su empleo
en un ensayo terapéutico antigiardiasico. Rev. Cubana
Med. Trop. 55, 174-178, 2003.
[32] Escobedo A.A., Cañete R., González M.E., Pareja
A.. Cimerman S., Almirall P. A randomized trial comparing mebendazole and secnidazole against giardiasis. Ann. Trop. Med. Parasitol. 97, 499-505, 2003.
[33] Escobedo A.A., Núñez F.A., Moreira I., Vega E.,
Pareja A., Almirall P. Comparison of chloroquine, albendazole and tinidazole in the treatment of children with
giardiasis. Ann. Trop. Med. Parasitol. 97, 367-371, 2003.
[34] Cañete R., Escobedo A.A., González M.E., Almirall
P., Cantelar N. A randomised controlled open label trial of a single day of mebendazole versus a single dose
of tinidazole in the treatment of giadiasis in children.
Curr. Med. Res. Opin. 22, 2131-2136, 2006.
[35] Núñez F.A., Escobedo A., Finlay C.M. Eficacia de
varios esquemas de tratamiento para la infección por
Giardia lamblia en niños. Rev. Panamericana Infectol. 6,
17-20, 2004.
[36] Cañete R., Ribas D., Escobedo A.A., González M.E.,
Almirall P., Brito K. A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children. West
Indian Med. J. 59, 607-611, 2010.
[37] Escobedo A.A., Álvarez G., González M.E., et al.
The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann.
Trop. Med. Parasitol. 102, 199-207, 2008.
[38] Escobedo AA, Piñeiro Fernández E, Almirall Carbonell P, Izquierdo Cirer A, Rodríguez Peña MS. Enfermedades del aparato digestivo: Parasitismo intestinal.
In: Castro Pacheco BL, Machado Lubián MC, López
González LR. Pediatría. Diagnóstico y tratamiento. 3er
ed. La Habana: Ciencias Médicas; 2016.p 243-48.
[39] Fung H.B., Doan T.L. Tinidazole: a nitroimidazole
antiprotozoal agent. Clin. Ther. 27, 1859-1884, 2005.
[40] Gazder A.J., Banerjee M. Single dose therapy of
giardiasis with tinidazole and metronidazole. Drugs 15
Suppl 1, 30-32, 1978.
[41] Jokipii L., Jokipii A.M. Single-dose metronidazole
and tinidazole as therapy for giardiasis: success rates,
side effects, and drug absorption and elimination. J. Infect. Dis. 140, 984-988, 1979.
[42] Sabchareon A., Chongsuphajaisiddhi T., Attanath
P. Treatment of giardiasis in children with quinacrine,
metronidazole, tinidazole and ornidazole. Southeast
Asian J. Trop. Med. Public Health 11, 280-284, 1980.
[43] Kyrönseppä H., Pettersson T. Treatment of giardiasis: relative efficacy of metronidazole as compared with
tinidazole. Scand. J. Infect. Dis. 13, 311-312, 1981.
[44] Bassily S., Farid Z., el-Masry N.A., Mikhail E.M.
Treatment of intestinal E. histolytica and G. lamblia with
metronidazole, tinidazole and ornidazole: a comparative study. J. Trop. Med. Hyg. 90, 9-12, 1987.